Trending
- Why too many women are prescribed antibiotics for UTIs they don’t have
- New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Canadian employee well-being continues to decline as employers struggle to measure and improve outcomes
- Psychology says people who save screenshots they never look at may be collecting a sense of future security
- Ozempic adds another layer to the shame game
- MRF-D Marines kick off multinational exercise Super Garuda Shield 26 in Indonesia
- Global Markets for Fermentation Ingredients to Reach $53.4 Billion by 2031, Driven by Rising Demand for Animal Nutrition Ingredients
- Home health, hospice deal-making on track to soar in 2027, report predicts
Monday, August 31